Aura, Cabaletta Complete Major Public Offerings This Week
Tap title to read story
Boston — Aura Biosciences announced on May 4 that it priced an underwritten public offering of common stock and pre-funded warrants, offering 39,591,000 shares and up to 3,800,000 pre-funded warrants at $6.00 and $5.99999 respectively; the company granted underwriters a 30-day option for additional shares.
Boston and Philadelphia reports this week show related financing activity in the biotech sector: Aura reported the offering closed on May 5 with full exercise of the underwriters’ option, generating approximately $299.4 million in gross proceeds, while Cabaletta priced an at-the-market offering on May 4 expected to raise about $150 million with institutional participation, including Eli Lilly.
More context
Timeline
- 1. May 4, 2026 — Aura announced launch of an underwritten public offering via GlobeNewswire.
- 2. May 4, 2026 — Cabaletta Bio priced an at-the-market offering expected to raise about $150 million.
- 3. May 4, 2026 — Aura priced 39,591,000 shares and up to 3,800,000 pre-funded warrants at $6.00/$5.99999.
- 4. May 5, 2026 — Aura closed the offering, with underwriters fully exercising the option; gross proceeds about $299.4 million.
- 5. May 5–6, 2026 — News outlets published the pricing and closing notices, listing underwriters and participating investors.
Why it matters
These public offerings by Aura and Cabaletta are big moves in the biotech sector. They show investor confidence, which can influence the stock market. If you're invested in biotech or considering it, keep an eye on these companies.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
